Liposome-encapsulated panomycocin: preparation, characterization and in-vitro determination of antifungal efficacy against vulvovaginal candidiasis

Bayram, Günce
Vulvovaginal candidiasis is a serious yeast infection that affects 80% of all women worldwide. In this study, a liposomal lyophilized powder formulation of Panomycocin was developed for therapeutic purposes against vulvovaginal candidiasis. Panomycocin is a potent antimycotic/antifungal protein secreted by Pichia anomala NCYC 434 strain previously shown to be fungicidal against Candida species which are the causal agents of vulvovaginal candidiasis. This study consists of the preparation of stratum corneum liposomes with a lipid composition identical to that of the vaginal epithelium, loading of the liposomes with Panomycocin, characterization of the liposomes and determination of biological activity of Panomycocin loaded liposomes on an in vitro human vaginal epithelium tissue model. In TEM analyses the liposomes showed size in the nano scale and regular morphology. The encapsulation and loading efficiencies of liposome nanoparticles were found as 73% and 76.8% respectively. Zeta potential measurements revealed uniform charge distribution on nanoparticle surfaces and stable nanoparticles. FTIR analyses revealed the lack of covalent interactions between encapsulated Panomycocin and liposome nanoparticles. DLS analyses showed that the nanoparticles have uniform size distribution. XRD analyses showed that they were amorphous. The liposomes released 1.71% of encapsulated Panomycocin in aqueous solution. All encapsulated Panomycocin was released when the liposomal lyophilized powder formulation was applied on in vitro human vaginal epithelium tissue model contaminated with Candida species; yielding MFC values comparable to that of pure Panomycocin. This liposomal lyophilized powder formulation of Panomycocin prepared specially with stratum corneum lipids may be subjected to further preclinical and clinical trials to develop an effective antimycotic/antifungal drug for the treatment of vulvovaginal candidiasis.


Liposome-encapsulated panomycocin: preparation, characterization and in vitro determination of antifungal efficacy against dermatophytes
Tosun, Kübra; İzgü, Kadri Fatih; Özkan, Yalçın; Department of Biotechnology (2016)
Dermatopytosis is one of the most seen superficial fungal infections in humans resulting mild to severe inflammations. Antifungal drugs are not effective in the treatment of dermatophytosis due to serious adverse effects and resistance developed by fungal pathogens. Thus, the development of safe, naturally derived and potent antifungal/antimycotic agents which do not result in resistance and elicit little or no side effects to mammalian cells with high selectivity to the fungal pathogens is a continuing nee...
VanA-Type MRSA (VRSA) Emerged in Surface Waters
İçgen, Bülent (Springer Science and Business Media LLC, 2016-09-01)
Due to the widespread occurrence of mecA-encoded methicillin resistance in Staphylococcus aureus (MRSA), treatment of staphylococcal infections is shifted to glycopeptide antibiotics like vancomycin and teicoplanin. The selective pressure of glycopeptides has eventually led to the emergence of staphylococci with increased resistance. Of great concern is vanA-encoded high level vancomycin and teicoplanin resistance in MRSA (VRSA). Therefore, this study aimed at investigating the occurrence of VRSA in surface...
Stratum corneum lipid liposome-encapsulated panomycocin: preparation, characterization, and the determination of antimycotic efficacy against Candida spp. isolated from patients with vulvovaginitis in an in vitro human vaginal epithelium tissue model
İzgü, Kadri Fatih; Tosun, Kubra; Izgu, Demet (2017-01-01)
In this study, a liposomal lyophilized powder formulation of panomycocin was developed for therapeutic purposes against vulvovaginal candidiasis which affects 80% of women worldwide. Panomycocin is a potent antimycotic protein secreted by the yeast Wickerhamomyces anomalus NCYC 434. This study involved the preparation of panomycocin-loaded stratum corneum lipid liposomes (SCLLs), characterization of the SCLLs, and determination of antimycotic efficacy of the formulation against Candida albicans and Candida ...
vanA-targeted oligonucleotide DNA probe designed to monitor vancomycin- and teicoplanin-resistant bacteria in surface waters
Nakipoğlu, Mustafa; İçgen, Bülent (2016-10-01)
The glycopeptide antibiotics teicoplanin and vancomycin are common to treat severe Gram-positive bacterial infections. The gene vanA confers high-level resistance to these antibiotics, and these phenomena have been shown to be transferable. Release of vancomycin-and teicoplanin-resistant bacteria to surface waters is, therefore, of particular concern since they might proliferate and spread in different environments. Monitoring of the fate of vanA gene in these waters provides information on the exposure and...
Backbone resonance assignments of a promiscuous aminoglycoside antibiotic resistance enzyme; the aminoglycoside phosphotransferase(3')-IIIa
Serpersu, Engin H.; Özen, Can; Norris, Adrianne L.; Steren, Carlos; Whittemore, Neil (2010-04-01)
The aminoglycoside phosphotransferase(3')-IIIa (APH) is a promiscuous enzyme and renders a large number of structurally diverse aminoglycoside antibiotics useless against infectious bacteria. A remarkable property of this similar to 31 kDa enzyme is in its unusual dynamic behavior in solution; the apo-form of the enzyme exchanges all of its backbone amide protons within 15 h of exposure to D (2) O while aminoglycoside-bound forms retain similar to 40% of the amide protons even after > 90 h of exposure. More...
Citation Formats
G. Bayram, “Liposome-encapsulated panomycocin: preparation, characterization and in-vitro determination of antifungal efficacy against vulvovaginal candidiasis,” M.S. - Master of Science, Middle East Technical University, 2016.